Funding will enable ViAqua to bring its first product to market, invest in R&D for future products, and prove the platform’s ability to deliver RNA-based solutions at scale. HAIFA, Israel, Sept. 5, 2023 /PRNewswire/ — ViAqua Therapeutics, a biotechnology company and developer of an…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.